Viemed Healthcare US ((VMD)) has held its Q1 earnings call. Read on for the main highlights of the call.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Viemed Healthcare’s recent earnings call paints a picture of optimism and growth, despite some challenges on the horizon. The company reported strong financial performance, effective sales restructuring, and strategic acquisitions that are set to drive future growth. However, regulatory changes, declining gross margins, and stalled opportunities with the VA present challenges that the company must navigate.
Strong Financial Performance
Viemed Healthcare showcased impressive financial results, with organic revenue increasing by 14.5% and total revenue up by 16.9%. The adjusted EBITDA grew by 26% for the quarter, reaching $12.8 million, and the adjusted EBITDA margin improved to 21.6%, marking a 160 basis point increase from the previous year.
Vent and Sleep Business Growth
The company’s vent business, although experiencing a slight 3% sequential decline, achieved a 10% year-over-year increase. Meanwhile, the sleep business demonstrated robust growth, with a 7% sequential increase in sleep therapy patients and a remarkable 46% increase year-over-year.
Acquisition of Lehan’s Medical Equipment
Viemed has strategically expanded its reach by signing an agreement to acquire Lehan’s Medical Equipment for $26 million. This acquisition is expected to enhance their presence in the respiratory and women’s health markets.
Effective Sales Restructuring
The sales restructuring efforts implemented last year have borne fruit, resulting in a 9% sequential increase in new patient starts for vent patients, positively impacting future business outcomes.
Positive Regulatory Environment
Recent regulatory changes, such as the CMS proposed national policy coverage determination on noninvasive positive pressure ventilation, are perceived as favorable and moving in the right direction for Viemed.
Regulatory Challenges
Despite the positive regulatory environment, the potential cuts to Medicaid and Medicare pose challenges. However, Viemed believes these pressures could play to their strengths.
Decline in Gross Margin
The company’s gross margin has declined to 56.3% for the quarter, down from 58.9% in the first quarter of 2024 and 59.5% in the fourth quarter of 2024, attributed to changes in the product and service mix.
Uncertain Impact of Tariffs
The potential impact of tariffs remains uncertain, although current supplier contracts are largely secured for 2025, providing some stability.
VA Opportunity Stalled
The anticipated growth opportunity with the VA has stalled due to administrative challenges, which is a setback for the company’s expansion plans.
Forward-Looking Guidance
Looking ahead, Viemed Healthcare has set ambitious targets for 2025. The company projects full-year net revenues between $254 million and $265 million, with adjusted EBITDA expected to grow by 11% over 2024, ranging from $54 million to $58 million. The strategic acquisition of Lehan’s Medical Equipment is expected to bolster their offerings and market presence.
In summary, Viemed Healthcare’s earnings call reflects a positive outlook with strong financial performance and strategic initiatives paving the way for future growth. While challenges such as regulatory changes and declining margins exist, the company is well-positioned to capitalize on its strengths and continue its upward trajectory.